Clinical Trial

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Study acronym: CREATE-1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-15; most recent amendment 2026-02-17.
Status change: Active, Not Recruiting → Recruiting 2023-04-07
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-02-07
Trial Details
NCT Number NCT05626712
Lead Sponsor Creative Medical Technology Holdings Inc
Conditions Type 1 Diabetes, Diabetes Mellitus, Type 1
Enrollment 18 participants
Start Date 2023-04-07
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-19